SELLAS Life Sciences, a late-stage clinical biopharmaceutical company specializing in cancer therapies, recently made several significant announcements. The company received a positive recommendation from the Independent Data Monitoring Committee (IDMC) for its Phase 3 REGAL study. The IDMC assessed the efficacy and safety data and recommended the continuation of the REGAL trial patients’ treatment and follow-up without any modifications.
The Phase 3 REGAL study is a crucial trial for SELLAS Life Sciences as it evaluates the efficacy of its novel therapy in a broad range of cancer indications. The positive recommendation from the IDMC indicates that the treatment is showing promise and is safe for patients. This recommendation provides a boost to the company’s ongoing efforts to develop innovative therapies for cancer patients.
In addition to the positive IDMC recommendation, SELLAS Life Sciences also announced a change in the date and time for the presentation of data from the acute myeloid leukemia cohort of patients in the Phase 1 dose-escalation study of SLS009. The presentation will now take place on Friday, March 1, 2024, at 12:55 pm CEST, at the 2024 European School of Haematology Acute Leukaemias (ESH) Conference in Stockholm, Sweden. This presentation will provide valuable insights into the results and progress of SLS009, offering hope to patients suffering from acute myeloid leukemia.
SELLAS Life Sciences is actively promoting its research and development efforts. The company recently published preclinical data on its highly selective CDK9 inhibitor, SLS009, in Oncotarget, a reputable medical publication. This publication highlights the underlying mechanisms of action behind the anti-proliferative effects of SLS009 in various hematologic malignancies. By sharing this data, SELLAS Life Sciences demonstrates its commitment to transparency and knowledge sharing within the medical community.
Comments